Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 31/5/2020
SIETES contiene 93020 citas

 
 
 1 a 20 de 42 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010;33:713-26. [Ref.ID 89267]
2. Cita con resumen
Venkatakrishnan K. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80. [Ref.ID 49421]
3.
Brockmeyer NH, Barthel B, Mertins L, Goos M. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alfa and -ß. Int J Clin Pharmacol Ther 1998;36:309-11. [Ref.ID 38577]
4.
Lanchote VL, Ping W C, Santos SRCJ. Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. Ther Drug Monit 1997;19:705-10. [Ref.ID 36288]
5.
Vessell ES, DeAngelo TM, Katz IR. Reproducibility of antipyrine half-lives in elderly subjects. Clin Pharmacol Ther 1993;54:150-7. [Ref.ID 20395]
6.
St Peter JV, Awni WM. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 1991;20:50-65. [Ref.ID 15925]
7. Cita con resumen
Brogden RN. Pyrazolone derivatives. Drugs 1986;32:60-70. [Ref.ID 10735]
8. Cita con resumen
Ortuño J, Botella J. Recurrent acute renal failure induced by phenazone hypersensitivity. Lancet 1973;2:1473-6. [Ref.ID 10504]
9.
Brovon DM, Hardy TL. Short-term study of the effect of phenacetin, phenazone and amidopyrine on the rat kidney. Br J Pharmacol Chemother 1968;32:17-24. [Ref.ID 10496]
10.Tiene citas relacionadas
Axelsson U. Papillitis necroticans renalis och hemolytisk anemi hos fenazonmissbrukare. Nord Med Tidskr 1958;59:903-4. [Ref.ID 10494]
11.
Gachályi B, Vas Á, Csillag K, Nagy B, Kocsis F, Káldor A. Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine. Eur J Clin Pharmacol 1987;31:613-5. [Ref.ID 9823]
12.
Anónimo. Drug control authority bans seven undesirable drugs. Lancet 1986;2:1210. [Ref.ID 9738]
13.
Staiger Ch, Jauernig R, De Vries J, Weber E. Influence of amiodarone on antipyrine pharmacokinetics in three patients with ventricular tachycardia. Br J Clin Pharmacol 1984;18:263-4. [Ref.ID 8338]
14.
Riester E F, Pantuck EJ, Pantuck CB, Passananti G T, Vesell ES, Conney AH. Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther 1980;28:384-91. [Ref.ID 6417]
15.
Chapman PH, Keys B, Rawlins M D, Moss C, Shuster S. Antipyrine clearance in psoriasis. BMJ 1981;282:20-1. [Ref.ID 6391]
16.
17.
Wood AJJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979;26:16-20. [Ref.ID 5181]
18.
Smith AM. Antipyrine for prophylaxis of neonatal jaundice. Lancet 1979;1:503. [Ref.ID 4854]
19.
Lewis PJ, Friedman LA. Prophylaxis of neonatal jaundice with maternal antipyrine treatment. Lancet 1979;1:300-2. [Ref.ID 4816]
20.
Swift CG, Homeida M, Halliwell M, Roberts C J C. Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 1978;14:149-52. [Ref.ID 4738]
Seleccionar todas
 
 1 a 20 de 42 siguiente >>